Corcept

Menlo Park, United States Founded: 1998 • Age: 28 yrs Listed
Developer of cortisol modulators for the treatment of various diseases

About Corcept

Corcept is a publicly listed company based in Menlo Park (United States) founded in 1998. The company has 500 employees. Its website corcept.com draws about 38 thousand monthly visits. Corcept offers products and services including Cortisol Modulation Pipeline. Its focus areas include Life Sciences, Metabolic Diseases and Drugs. Its legal entity is Corcept Therapeutics, Incorporated. Its competitors include NGM Biopharmaceuticals, MannKind Corp and Rhythm Pharmaceuticals; 3 of its 3 listed competitors have raised funding.

Company details

Developer of cortisol modulators for the treatment of various diseases. The company focuses on the discovery and development of drugs that modulate the effects of cortisol that target glucocorticoid receptor (GR) antagonists to treat a variety of endocrine, metabolic, oncologic, psychiatric, and ophthalmologic diseases.

  • Headquarters Menlo Park, United States
  • Employees 500
  • Stage Public
  • Sectors
    Healthcare
  • Website category Finance · Investing
  • Website corcept.com
  • Social LinkedIn X YouTube
  • Legal Name Corcept Therapeutics Incorporated
Operational Areas
Key Metrics
  • Annual Revenue
    $761.41 M (USD)
    12.79
    as on Dec 31, 2025
  • Net Profit
    $98.17 M (USD)
    -29.74
    as on Dec 31, 2025
  • EBITDA
    $46.69 M (USD)
    -66.24
    as on Dec 31, 2025
  • Investors
  • Employee Count
    500

Products & Services of Corcept

Corcept offers a comprehensive portfolio of products and services, including Cortisol Modulation Pipeline.

Cortisol Modulation Pipeline
Therapeutic Development

Develops treatments for diseases affected by cortisol through clinical trials.

Apps and channels of Corcept

its YouTube channel Corcept Therapeutics has 50 subscribers and 3 videos.

Corcept Therapeutics
YouTube 50 subscribers 3 videos Science & Technology
Open channel

Videos from Corcept

The most watched videos on Corcept's YouTube channel, Corcept Therapeutics (50 subscribers). Click a video to play it here.

Corcept: The Cortisol Modulation Company
548 views
Deile’s Hypercortisolism Diagnosis
204 views
How Ed’s Hypercortisolism Diagnosis Changed His Life
132 views

More on Corcept Therapeutics.

Funding Insights of Corcept

  • Total Rounds 6
  • First Round $3M

    (Nov 2006)

  • Investors Count 5

All 6 funding rounds of Corcept with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jun 2011Post-IPO––
Apr 2010$7.65MPost-IPO––
–
Oct 2009$18.01MPost-IPO––
–
Mar 2008$25.3MPost-IPO––
Aug 2007$10.11MPost-IPO––
Nov 2006$3MPost-IPO––
–
Valuation history

5 investors in total: 5 institutional.

Investors in Corcept

Corcept has secured backing from 5 investors, including venture fund investors. Prominent investors backing the company include Investor Growth Capital, Longitude Capital and Sutter Hill Ventures.

All
Venture Fund
InvestorDescriptionFounded YearDomainLocation
Corporate-backed venture capital firm focused on fintech, energy, and multiple sectors
investorgrowthcapital.comNew York, United States
Private equity firm focused on life science sector
longitudecapital.comMenlo Park, United States
VC firm investing in the US
shv.comPalo Alto, United States
Venture capital firm focused on healthcare companies
altapartners.comJackson, United States
Funding is provided for breakout consumer brands by Paperboy Ventures.
paperboyventures.com
Premium access

Investor details for Corcept

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Corcept

179 people are tracked at Corcept (81 in leadership, 6 in board & advisors, 92 in team); the tracked headcount is 500.

NameRoleGroup
Joseph K Belanoff
CEO, President & DirectorLeadership
Charles Robb
Chief Business OfficerLeadership
Niral Shah
Associate Director, Clinical Data ManagementLeadership
Jeff Dener
Director Of Chemical DevelopmentLeadership
Jana Cranmer Chow
Senior Director, Corporate CommunicationsLeadership
Will K.
Director, Pipeline & Portfolio Market PlanningLeadership
Kavitha Seenivasan
Associate Director, Clinical Data ManagementLeadership
Amy Flood
Chief Human Resources & Communications OfficerLeadership
Amiel Balagtas
Vice President, Development OperationsLeadership
Alan Arroyo
Vice President, Clinical Development OperationsLeadership
Anupma Roy
Director Of Clinical OperationsLeadership
Danielle Cascerceri
Senior Director, Franchise StrategyLeadership
Liz Ruskay
Associate Director, Learning & DevelopmentLeadership
Steven Ross
Vice President Human ResourcesLeadership
Alejandra Preciado
Associate Director, Financial Planning & AnalysisLeadership
Lauren Wiser
Senior Director Product DevelopmentLeadership
Heather Zimmerman
Senior Director, LegalLeadership
Kanoti Kim
Vice President, Financial Planning And AnalysisLeadership
Shameek Ghose
Vice President, Intellectual PropertyLeadership
Gavin Williams
Vice President, Market Planning & Operations | General ManagerLeadership

159 more people are available in the full profile.

Premium access

Complete people profiles for Corcept

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Corcept

Corcept is a publicly listed company on the NASDAQ with ticker symbol CORT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date14 Apr 2004
  • Listed onNASDAQ: CORT
  • Listed entityCorcept Therapeutics Incorporated
  • Exchange sectorHealth technology
  • ISINUS2183521028
  • Share price$117.80 (-2.8% on the day) · 2026-10-13
  • Market capitalisation$12.73B
  • Price to earnings281.3
  • EPS (diluted, trailing year)$0.42
  • Volume (last session)556,291

Financials of Corcept

Exchange-reported annual figures
YearRevenueNet incomeEBITDA
2025$761.4M$98.2M$46.7M
2024$675.0M$139.7M$138.3M
2023$482.4M$105.5M$108.3M
2022$401.9M$101.3M$115.6M
2021$366.0M$112.5M$127.5M
Premium access

Detailed financial statements for Corcept

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Timeline of Corcept

4 dated milestones of Corcept across 13 years, from founding to its latest funding, stage changes and deals.

  1. Founded Corcept is founded.
  2. IPO Lists on the stock exchange (IPO).
  3. Funding First funding round of $3.0M.
  4. Funding Latest funding round, Post-IPO,.

Competitors of Corcept

Corcept has 3 listed competitors in our database, 3 of them funded. They include NGM Biopharmaceuticals, MannKind Corp and Rhythm Pharmaceuticals.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
ngmbio.com2007San Francisco, United States$358.87M225
Biologics are developed for cardio-metabolic and liver diseases.
mannkindcorp.com1991Los Angeles, United States$50M322
Developer of small-molecule drugs
rhythmtx.com2010Boston, United States$84M115
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
Premium access

Detailed competitors of Corcept

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Corcept

The website of Corcept (corcept.com) receives about 38.2K visits a month and ranks #779,816 among all websites worldwide, #7,452 in Investing.

  • Monthly visits
    38.2K

    ▲ 13.3% vs previous month

  • Unique visitors
    15.7K

    per month

  • Global rank
    #779,816

    among all websites

  • Category rank
    #7,452

    Finance · Investing

Top companies in Metabolic Diseases

3 companies that operate in the same segment as Corcept (Metabolic Diseases) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Satiety induction through digestable gastric balloon introduced via a swallowed capsule
2009Wellesley, Massachusetts, United StatesUSD 174.04 MUSD 32.11 M137
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
2010Boston, Massachusetts, United StatesUSD 84 MUSD 189.76 M283
Developer of small-molecule drugs
1991Los Angeles, California, United StatesUSD 50 MUSD 348.97 M407
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Corcept

Premium access

Complete news archive for Corcept

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Corcept

Corcept was founded in 1998 and raised its 1st funding round 8 years after it was founded.

Corcept is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.

Corcept has 500 employees.

Annual revenue of Corcept is $761.41M as on Dec 31, 2025.

Developer of cortisol modulators for the treatment of various diseases. The company focuses on the discovery and development of drugs that modulate the effects of cortisol that target glucocorticoid receptor (GR) antagonists to treat a variety of endocrine, metabolic, oncologic, psychiatric, and ophthalmologic diseases.

Corcept's top competitors include Rhythm Pharmaceuticals, MannKind Corp and NGM Biopharmaceuticals.

Corcept offers Cortisol Modulation Pipeline.

Yes, Corcept is publicly traded on NASDAQ under the ticker symbol CORT.

Corcept has 5 investors. Key investors include Investor Growth Capital, Longitude Capital, Sutter Hill Ventures, Alta Partners, and Paperboy Ventures.

Corcept operates through Corcept Therapeutics, Incorporated.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available